Xencor Narrows Q4 Loss to $0.09, Revenue Beats by 30.6%
Xencor reported a fourth-quarter adjusted loss of $0.09 per share, beating the consensus estimate by $0.55 and improving from a $0.62 loss a year ago. Revenue declined 46.5% year-over-year to $28.24 million but topped estimates by 30.6%, with the company highlighting lead candidate XmAb819 in advanced ccRCC.
1. Q4 Financial Results
Xencor posted an adjusted loss of $0.09 per share in the fourth quarter, surpassing forecasts by $0.55 and improving from a $0.62 loss in the year-ago period. The company generated $28.24 million in revenue, exceeding consensus by 30.6% despite a 46.5% decline from $52.79 million a year earlier.
2. Stock Performance and Outlook
Shares have declined about 22.9% year to date as investors weigh mixed top-line trends against consecutive earnings surprises. Consensus forecasts call for a $0.66 loss per share and $21.13 million in revenue next quarter, with full-year estimates at a $2.65 loss on $87.98 million in sales.
3. Pipeline Highlight
Management spotlighted XmAb819, a first-in-class T-cell engager targeting advanced clear cell renal cell carcinoma, as a potential clinical catalyst for the coming quarters.